Assenagon Asset Management S.A. Reduces Holdings in Cryoport, Inc. (NASDAQ:CYRX)

Assenagon Asset Management S.A. trimmed its holdings in shares of Cryoport, Inc. (NASDAQ:CYRX) by 9.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,334,315 shares of the company’s stock after selling 143,378 shares during the quarter. Assenagon Asset Management S.A. owned approximately 2.70% of Cryoport worth $10,381,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in CYRX. Bank of New York Mellon Corp grew its position in shares of Cryoport by 13.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 169,155 shares of the company’s stock valued at $1,169,000 after acquiring an additional 19,803 shares during the period. Rhumbline Advisers lifted its position in Cryoport by 3.4% during the second quarter. Rhumbline Advisers now owns 64,158 shares of the company’s stock valued at $443,000 after purchasing an additional 2,086 shares in the last quarter. Federated Hermes Inc. bought a new stake in Cryoport during the second quarter valued at about $774,000. Massachusetts Financial Services Co. MA increased its position in Cryoport by 2.6% in the second quarter. Massachusetts Financial Services Co. MA now owns 2,035,586 shares of the company’s stock worth $14,066,000 after buying an additional 52,103 shares in the last quarter. Finally, Hsbc Holdings PLC bought a new position in shares of Cryoport in the second quarter worth about $92,000. 92.90% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Cryoport

In other news, CEO Jerrell Shelton sold 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $6.78, for a total value of $339,000.00. Following the completion of the sale, the chief executive officer now owns 712,747 shares of the company’s stock, valued at approximately $4,832,424.66. This represents a 6.56 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ramkumar Mandalam sold 7,369 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $7.46, for a total transaction of $54,972.74. Following the transaction, the director now owns 59,497 shares in the company, valued at approximately $443,847.62. This represents a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 109,869 shares of company stock valued at $735,673 in the last ninety days. Corporate insiders own 10.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on CYRX. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price objective on shares of Cryoport in a research note on Friday. Guggenheim assumed coverage on shares of Cryoport in a research report on Thursday, December 19th. They issued a “buy” rating and a $11.00 price target for the company. UBS Group raised their price objective on shares of Cryoport from $7.00 to $9.00 and gave the company a “neutral” rating in a research report on Friday, October 18th. Finally, Roth Mkm dropped their target price on shares of Cryoport from $18.00 to $15.00 and set a “buy” rating for the company in a report on Friday, November 8th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $12.29.

Cryoport Trading Up 0.1 %

Shares of CYRX opened at $7.50 on Friday. The firm has a market capitalization of $370.73 million, a price-to-earnings ratio of -2.22 and a beta of 1.58. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.70 and a quick ratio of 5.32. Cryoport, Inc. has a 1-year low of $5.32 and a 1-year high of $20.10. The company has a 50-day moving average of $7.68 and a 200 day moving average of $7.86.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.